As Biotechnology companies, Compugen Ltd. (NASDAQ:CGEN) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) are our subject to contrast. And more specifically their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen Ltd.	17.80M	13.43	22.60M	-0.40	0.00
BioXcel Therapeutics Inc.	N/A	0.00	19.27M	-1.04	0.00

Table 1 highlights Compugen Ltd. and BioXcel Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

	Net Margins	Return on Equity	Return on Assets
Compugen Ltd.	-126.97%	-61.8%	-46.5%
BioXcel Therapeutics Inc.	0.00%	-40.1%	-37.6%

Liquidity

The Current Ratio of Compugen Ltd. is 4.7 while its Quick Ratio stands at 4.7. The Current Ratio of rival BioXcel Therapeutics Inc. is 23.3 and its Quick Ratio is has 23.3. BioXcel Therapeutics Inc. is better equipped to clear short and long-term obligations than Compugen Ltd.

Insider & Institutional Ownership

Roughly 20.1% of Compugen Ltd. shares are owned by institutional investors while 20.6% of BioXcel Therapeutics Inc. are owned by institutional investors. Insiders owned 12% of Compugen Ltd. shares. Comparatively, BioXcel Therapeutics Inc. has 1.1% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Compugen Ltd.	-5.32%	3.19%	6.91%	-8.72%	-6.32%	64.06%
BioXcel Therapeutics Inc.	8.12%	66.42%	85.45%	-0.45%	0%	131.09%

For the past year Compugen Ltd.’s stock price has smaller growth than BioXcel Therapeutics Inc.

Summary

On 6 of the 9 factors BioXcel Therapeutics Inc. beats Compugen Ltd.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.